Drugs used to treat insomnia in 2002: Regulatory-based rather than evidence-based medicine

Sleep

Volumn 27, Issue 8, 2004, Pages 1441-1442

  Walsh, James K ^a,b  

^a SAINT LOUIS UNIVERSITY   (United States)

^b Sleep Medicine and Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; CLONAZEPAM; CYCLOBENZAPRINE; DIPHENHYDRAMINE; DOXEPIN; FLURAZEPAM; HYDROXYZINE; LORAZEPAM; MIRTAZAPINE; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRAZODONE; ZALEPLON; ZOLPIDEM;

DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; INSOMNIA; MEDICAL AUDIT; PRIORITY JOURNAL;

EID: 11144334174     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/27.8.1441     Document Type: Editorial

References (4)

1. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999;22: 371-5.
2. Roehrs T, Roth T. 'Hypnotic' prescription patterns in a large managed-care population. Sleep Med 2004;5:463-6.
3. Krystal A, Walsh JK, Laska G, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-9.
4. Mendelson WB, Roth T, Cassella J, et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev 2004;8:7-17.